Ceremorphic Life Sciences CEO Delivers Keynote at AI Driven Drug Discovery Summit; Demonstrates New Bio-supercomputing Platform that Can Speed Every Phase of Drug Discovery and Development
- New BioCompDiscoverX® system leverages analog, quantum, and AI technology to drive new levels of efficiency in the entire drug development pipeline
- The ability to significantly lower development costs, shorten time-to-market and improve efficacy will deliver billions of dollars in savings to the pharmaceutical Industry
- CEO Venkat Mattela demonstrated the BioCompDiscoverX system features for the first time on stage during show keynote; unveiling new technology details around the platform
December 5, 2023, San Jose, CA – Ceremorphic Life Sciences CEO Venkat Mattela delivered the keynote at today’s AI Driven Drug Discovery Summit in Boston MA, where he demonstrated the company’s new BioCompDiscoverX supercomputing platform. Leveraging proprietary analog, quantum and AI technology, this new platform will allow Ceremorphic Life Sciences, a division of Ceremorphic, Inc., to begin developing drugs at a pace unprecedented in the pharmaceutical industry.
“With drug discovery becoming slower and more expensive over time, the BioCompDiscoverX platform will allow us to explore the early stages of drug discovery faster and more accurately in order to develop drugs at a rapid rate,” said Dr. Venkat Mattela, Founder and CEO of Ceremorphic. “This has not been possible to date – even on the most advanced computers – because they are missing the accurate models that can speed the emulation of cells and tissues; thereby better predicting outcomes early on to increase the R&D efficiency of the whole process. This is the critical capability that Ceremorphic Life Sciences brings to the industry, which has the potential to revolutionize drug design and make personalized medicine finally a reality and affordable.”
About BioCompDiscoverX
Ceremorphic’s Life Sciences leveraged a 5,000+ person-year effort spanning over 6 years in hardware, algorithms, and analog and quantum circuits to make In Silico Models more effective than traditional methods used today. This platform strives to enhance the scalability by minimizing the wet lab usage as much as possible and leverages the power of AI and high performance circuits. Ceremorphic Life Sciences works with its own foundation models generated through its own proprietary relevant data synthesis methods.
BioCompDiscoverX incorporates some key silicon technologies such as graph neural processing that can significantly accelerate drug discovery analysis. Some of the key components of the platform include an integrated quantum simulation environment that accelerates molecular dynamic simulations and protein-protein interaction study. The unique feature of the platform for vaccine generation is to study and converge on multiple vectors such as stability and translational efficiency with an unprecedented speed.
The platform includes a hardware model which assists in various phases of the design pipeline to increase the probability of success at later stages in order to reduce development time and provide greater efficiency. Because a critical part of the effective use of AI depends on having the relevant data for the model to get trained, Ceremorphic Life Sciences has developed unique technology to create the relevant data for AI foundation model creation using BioCompDiscoverX. This is key to the platform efficiency.
Dr. William Haseltine, former Professor at Harvard Medical School and Founder Chairman and CEO of Human Genome Sciences (HGS) also stated, “Current In Silico methods using the wet labs have limitations on scalability to produce enough data to use AI effectively. Ceremorphic’s hybrid approach utilizing analog circuit technology is unique. This approach not only accelerates computation speed, but also empowers AI to be highly effective throughout the entire development process.”
The BioCompDiscoverX will be available in Q3 2024 and will include technologies incorporated in its proprietary silicon device. Using this platform, Ceremorphic Life Sciences plans to develop pharmaceuticals and oversee the essential clinical trials. Ceremorphic Life Sciences will partner with R&D entities involved in drug discovery to accelerate the drug development process. The company will also collaborate with strategic partners who will be responsible for the manufacturing process of these novel drug offerings.
About Ceremorphic
Founded in April 2020, Ceremorphic currently has 160 full-time employees dedicated to solving the compute performance and energy efficiency requirements of AI supercomputing and Generative AI. Leveraging more than 200 patents and proven expertise in creating industry-leading silicon and system products, Ceremorphic has developed a ground-up architecture with century defining innovations that will transform both computing and life sciences fields. The company develops advanced system products based on its own silicon in TSMC 3nm process nodes. For more information, visit https://www.ceremorphic.com.
####
MEDIA CONTACT
Kelly Karr
+408-718-9350
Copyright 2023. All rights reserved. Ceremorphic is a registered trademark of Ceremorphic, Inc.